2016

SOLCO HEALTHCARE US, INTRODUCES DOXYCYCLINE HYCLATE DELAYED-RELEASE TABLETS, 150mg and 200mg

CRANBURY, NJ — Solco Healthcare is proud to announce its FDA approval for Doxycycline Hyclate delayed-release tablets, 150mg and 200mg, which are AB-rated equivalents to Doryx® by Mayne Pharmaceutical. “This new product launch demonstrates the capabilities of the Prinston/Solco team in developing, manufacturing and bringing a difficult to formulate product to market. As one of

SOLCO HEALTHCARE U.S. ANNOUNCES THE APPROVAL OF GENERIC VFEND ® TABLETS IN THE UNITED STATES

CRANBURY, NJ – August 11, 2016 – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Vfend ® Tablets (Voriconazole Tablets), 50 mg and 200 mg. The Company is preparing for the commercialization of this product and expects to launch the product soon. “We

SOLCO HEALTHCARE US, INTRODUCES DOXYCYCLINE HYCLATE DELAYED-RELEASE TABLETS, 150mg and 200mg

SOLCO HEALTHCARE U.S. ANNOUNCES THE APPROVAL OF GENERIC VFEND ® TABLETS IN THE UNITED STATES

Press Release Archives